dalfopristin (Synercid) Report issue

Small molecule Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Dalfopristin is a pristinamycin-like component of anti-bacterial drug called Synercid which also containes quinupristin (quinupristin:dalfopristin ratio is 30:70 (w/w)). The drug was approved by FDA and used for the treatment of skin diseases caused by Staphylococcus aureus or Streptococcus pyogenes. Dalfopristin binds to the RNA of the 50S ribosomal subunit and thus inhibits the late phase of protein synthesis.   NCATS

  • SMILES: CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(C)=C\[C@@H](O)CC(=O)CC3=NC(=CO3)C2=O
  • Mol. Mass: 690.847
  • ALogP: 2.27
  • ChEMBL Molecule:
More Chemistry

Combination drugs

( quinupristin, dalfopristin (Synercid) - other name: dalfopristin/quinupristin )
26-(2-diethylaminoethyl)sulfonylpristamycin iib | dalfopristin | dalfopristina | dalfopristine | dalfopristin mesilate | dalfopristin mesylate | dalfopristinum | rp 54476 | rp-54476 | synercid


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue